All these effects are related to its activation (which can occur in response to many ligands implicated in the pathogenesis of PAH, including endothelin-1, thromboxane-A2, and serotonin) and subsequent inhibition of the myosin light chain phosphatase activity [76–79]. This evidence concerns the gene EDN1 and pulmonary arterial hypertension.